Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground

Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground

Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.

CWEB Business News Pharmaceutical Giants Novo Nordisk and Eli Lilly Intensify Rivalry with Forthcoming Oral Obesity Drug Launches

In a major strategic shift, Novo Nordisk has announced a significant workforce reduction, eliminating approximately 9,000 positions globally. This move, representing 11% of its total workforce, is a direct response to mounting competitive pressure from rival Eli Lilly in the lucrative obesity and diabetes drug market. The restructuring is projected to yield savings of $1.25 […]

Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground – DG Verifications & Stats

In this article LLY NOVO.B-DK Follow your favorite stocksCREATE FREE ACCOUNT Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills. Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that’s best known for weekly shots. But after Lilly’s pill produced less we…